Tenaya Therapeutics Announces Board and Executive Changes

Ticker: TNYA · Form: 8-K · Filed: Dec 17, 2024

Sentiment: neutral

Topics: management-change, board-of-directors, executive-compensation

Related Tickers: TNYA

TL;DR

Tenaya Therapeutics (TNYA) board shakeup and exec comp changes filed. Watch for new director appointments and officer departures.

AI Summary

Tenaya Therapeutics, Inc. announced on December 16, 2024, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its named executive officers.

Why It Matters

Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board and executive changes can indicate internal shifts that may affect company strategy and performance, warranting closer investor scrutiny.

Key Numbers

Key Players & Entities

FAQ

Who are the specific officers or directors that have departed from Tenaya Therapeutics?

The filing indicates the departure of certain officers and directors but does not name them specifically in the provided text.

Who are the newly elected directors to the Tenaya Therapeutics board?

The filing states that directors have been elected, but their names are not specified in the provided text.

What specific changes have been made to the compensatory arrangements of certain officers?

The filing mentions updates to compensatory arrangements but does not detail the specific changes in the provided text.

What is the exact date of the report for Tenaya Therapeutics?

The report is dated December 17, 2024, with the earliest event reported on December 16, 2024.

What is the principal business address of Tenaya Therapeutics?

The principal executive offices are located at 171 Oyster Point Boulevard, Suite 500, South San Francisco, CA 94080.

Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2024-12-17 07:24:29

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENAYA THERAPEUTICS, INC. By: /s/ Jennifer Drimmer Rokovich Jennifer Drimmer Rokovich General Counsel and Secretary Date: December 17, 2024

View on Read The Filing